- Home
- ORMP vs ENTX Comparison
ORMP vs ENTX Comparison
Compare ORMP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | ENTX |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 142.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ORMP | ENTX |
|---|---|---|
| Price | $2.99 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 240.1K | 77.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.95 | ★ N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $1.82 | $1.50 |
| 52 Week High | $3.20 | $3.22 |
Technical Indicators
Market Signals| Indicator | ORMP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 32.95 |
| Support Level | $2.66 | $2.07 |
| Resistance Level | $3.19 | $2.22 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 61.12 | 5.42 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.